07-05-2024 | Cardiac Amyloidosis | Editorial
Collection on molecular imaging in cardiac amyloidosis
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Login to get accessPlease log in to get access to this content
Literature
1.
go back to reference Caobelli F. Recent evidence on Cardiac 99mTc-DPD Uptake after Therapy with Tafamidis May reveal the Road to an Ultra-early diagnosis in patients with ATTR Amyloidosis. J Nucl Med. 2024;65:329.CrossRefPubMed
Caobelli F. Recent evidence on Cardiac 99mTc-DPD Uptake after Therapy with Tafamidis May reveal the Road to an Ultra-early diagnosis in patients with ATTR Amyloidosis. J Nucl Med. 2024;65:329.CrossRefPubMed
2.
go back to reference Abadie B, Ali AH, Martyn T, Higgins A, Krishnaswamy A, Reed G, Puri R, Yun J, Cremer P, Hanna M, Tang WHW, Kapadia S, Jaber W. Prevalence of ATTR-CA and high-risk features to guide testing in patients referred for TAVR. Eur J Nucl Med Mol Imaging. 2023;50:3910–6.CrossRefPubMed
Abadie B, Ali AH, Martyn T, Higgins A, Krishnaswamy A, Reed G, Puri R, Yun J, Cremer P, Hanna M, Tang WHW, Kapadia S, Jaber W. Prevalence of ATTR-CA and high-risk features to guide testing in patients referred for TAVR. Eur J Nucl Med Mol Imaging. 2023;50:3910–6.CrossRefPubMed
3.
go back to reference Gotuzzo I, Slart RHJA, Gimelli A, Ashri N, Anagnostopoulos C, Bucerius J, Buechel RR, Gaemperli O, Gheysens O, Glaudemans AWJM, Habib G, Hyafil F, Lubberink M, Saraste A, Podlesnikar T, Dweck MR, Erba PA. Nuclear medicine practice for the assessment of cardiac sarcoidosis and amyloidosis. A survey endorsed by the EANM and EACVI. Eur J Nucl Med Mol Imaging. 2024 Apr;29. https://doi.org/10.1007/s00259-024-06727-5. Epub ahead of print.
Gotuzzo I, Slart RHJA, Gimelli A, Ashri N, Anagnostopoulos C, Bucerius J, Buechel RR, Gaemperli O, Gheysens O, Glaudemans AWJM, Habib G, Hyafil F, Lubberink M, Saraste A, Podlesnikar T, Dweck MR, Erba PA. Nuclear medicine practice for the assessment of cardiac sarcoidosis and amyloidosis. A survey endorsed by the EANM and EACVI. Eur J Nucl Med Mol Imaging. 2024 Apr;29. https://doi.org/10.1007/s00259-024-06727-5. Epub ahead of print.
4.
go back to reference Tingen HSA, Tubben A, van ‘t Oever JH, Pastoor EM, van Zon PPA, Nienhuis HLA, van der Meer P, Slart RHJA. Positron emission tomography in the diagnosis and follow-up of transthyretin amyloid cardiomyopathy patients: a systematic review. Eur J Nucl Med Mol Imaging. 2023;51:93–109.CrossRefPubMedPubMedCentral
Tingen HSA, Tubben A, van ‘t Oever JH, Pastoor EM, van Zon PPA, Nienhuis HLA, van der Meer P, Slart RHJA. Positron emission tomography in the diagnosis and follow-up of transthyretin amyloid cardiomyopathy patients: a systematic review. Eur J Nucl Med Mol Imaging. 2023;51:93–109.CrossRefPubMedPubMedCentral
5.
go back to reference Caobelli F, Braun M, Haaf P, Wild D, Zellweger MJ. Quantitative [99mTc]Tc-DPD SPECT/CT in patients with suspected ATTR cardiac amyloidosis: feasibility and correlation with visual scores. J Nucl Cardiol. 2020;27:1456–63.CrossRefPubMed
Caobelli F, Braun M, Haaf P, Wild D, Zellweger MJ. Quantitative [99mTc]Tc-DPD SPECT/CT in patients with suspected ATTR cardiac amyloidosis: feasibility and correlation with visual scores. J Nucl Cardiol. 2020;27:1456–63.CrossRefPubMed
6.
go back to reference Rettl R, Calabretta R, Duca F et al. Reduction in [99mTc]Tc-DPD myocardial uptake with therapy of ATTR cardiomyopathy. Amyloid. 2023:1–10.
Rettl R, Calabretta R, Duca F et al. Reduction in [99mTc]Tc-DPD myocardial uptake with therapy of ATTR cardiomyopathy. Amyloid. 2023:1–10.
7.
go back to reference Rettl R, Wollenweber T, Duca F, et al. Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2023;24:1019–30.CrossRefPubMedPubMedCentral
Rettl R, Wollenweber T, Duca F, et al. Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2023;24:1019–30.CrossRefPubMedPubMedCentral
8.
go back to reference Papathanasiou M, Kessler L, Bengel FM, et al. Regression of myocardial [99mTc]Tc-DPD uptake after Tafamidis Treatment of Cardiac Transthyretin Amyloidosis. J Nucl Med. 2023;64:1083–6.CrossRefPubMed
Papathanasiou M, Kessler L, Bengel FM, et al. Regression of myocardial [99mTc]Tc-DPD uptake after Tafamidis Treatment of Cardiac Transthyretin Amyloidosis. J Nucl Med. 2023;64:1083–6.CrossRefPubMed
9.
go back to reference Tingen HSA, Tubben A, Bijzet J, van den Berg MP, van der Meer P, Houwerzijl EJ, Muntinghe FLH, van der Zwaag PA, Glaudemans AWJM, Oerlemans MIFJ, Knackstedt C, Michels M, Hirsch A, Hazenberg BPC, Slart RHJA, Nienhuis HLA. Cardiac [99mTc]Tc-hydroxydiphosphonate uptake on bone scintigraphy in patients with hereditary transthyretin amyloidosis: an early follow-up marker? Eur J Nucl Med Mol Imaging. 2024;51:681–90.CrossRefPubMed
Tingen HSA, Tubben A, Bijzet J, van den Berg MP, van der Meer P, Houwerzijl EJ, Muntinghe FLH, van der Zwaag PA, Glaudemans AWJM, Oerlemans MIFJ, Knackstedt C, Michels M, Hirsch A, Hazenberg BPC, Slart RHJA, Nienhuis HLA. Cardiac [99mTc]Tc-hydroxydiphosphonate uptake on bone scintigraphy in patients with hereditary transthyretin amyloidosis: an early follow-up marker? Eur J Nucl Med Mol Imaging. 2024;51:681–90.CrossRefPubMed
10.
go back to reference Gheysens O, Treglia G, Masri A, Hyafil F, Dorbala S. Treatment response assessment in transthyretin-related cardiac amyloidosis: an emerging clinical indication of bone-seeking radiopharmaceuticals? Eur J Nucl Med Mol Imaging. 2024;51:691–4.CrossRefPubMed
Gheysens O, Treglia G, Masri A, Hyafil F, Dorbala S. Treatment response assessment in transthyretin-related cardiac amyloidosis: an emerging clinical indication of bone-seeking radiopharmaceuticals? Eur J Nucl Med Mol Imaging. 2024;51:691–4.CrossRefPubMed
11.
go back to reference Rischpler C, Kersting D, Kessler L, Varasteh Z, Luedike P, Carpinteiro A, Rassaf T, Herrmann K, Papathanasiou M, Reply. Recent evidence on Cardiac 99mTc-DPD Uptake after Therapy with Tafamidis May reveal the Road to an Ultra-early diagnosis in patients with ATTR Amyloidosis. J Nucl Med. 2024;65:330.CrossRefPubMed
Rischpler C, Kersting D, Kessler L, Varasteh Z, Luedike P, Carpinteiro A, Rassaf T, Herrmann K, Papathanasiou M, Reply. Recent evidence on Cardiac 99mTc-DPD Uptake after Therapy with Tafamidis May reveal the Road to an Ultra-early diagnosis in patients with ATTR Amyloidosis. J Nucl Med. 2024;65:330.CrossRefPubMed
12.
go back to reference Rettl R, Mann C, Duca F, Dachs TM, Binder C, Ligios LC, Schrutka L, Dalos D, Koschutnik M, Donà C, Kammerlander A, Beitzke D, Loewe C, Charwat-Resl S, Hengstenberg C, Kastner J, Eslam RB, Bonderman D. Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2022;23:767–80.CrossRefPubMed
Rettl R, Mann C, Duca F, Dachs TM, Binder C, Ligios LC, Schrutka L, Dalos D, Koschutnik M, Donà C, Kammerlander A, Beitzke D, Loewe C, Charwat-Resl S, Hengstenberg C, Kastner J, Eslam RB, Bonderman D. Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2022;23:767–80.CrossRefPubMed
13.
go back to reference Wang X, Guo Y, Gao Y, Ren C, Huang Z, Liu B, Li X, Chang L, Shen K, Ding H, Zhang H, Tian Z, Hacker M, Zhang S, Wang Y, Li J, Li X, Huo L. Feasibility of 68Ga-Labeled fibroblast activation protein inhibitor PET/CT in Light-Chain Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2022;15:1960–70.CrossRefPubMed
Wang X, Guo Y, Gao Y, Ren C, Huang Z, Liu B, Li X, Chang L, Shen K, Ding H, Zhang H, Tian Z, Hacker M, Zhang S, Wang Y, Li J, Li X, Huo L. Feasibility of 68Ga-Labeled fibroblast activation protein inhibitor PET/CT in Light-Chain Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2022;15:1960–70.CrossRefPubMed
14.
go back to reference Clerc OF, Cuddy SAM, Robertson M, Vijayakumar S, Neri JC, Chemburkar V, Kijewski MF, Di Carli MF, Bianchi G, Falk RH, Dorbala S. Cardiac amyloid quantification using 124I-Evuzamitide (124I-P5 + 14) Versus 18F-Florbetapir: a pilot PET/CT study. JACC Cardiovasc Imaging. 2023;16:1419–32.CrossRefPubMedPubMedCentral
Clerc OF, Cuddy SAM, Robertson M, Vijayakumar S, Neri JC, Chemburkar V, Kijewski MF, Di Carli MF, Bianchi G, Falk RH, Dorbala S. Cardiac amyloid quantification using 124I-Evuzamitide (124I-P5 + 14) Versus 18F-Florbetapir: a pilot PET/CT study. JACC Cardiovasc Imaging. 2023;16:1419–32.CrossRefPubMedPubMedCentral
Metadata
- Title
- Collection on molecular imaging in cardiac amyloidosis
- Authors
-
Federico Caobelli
Christoph Rischpler
- Publication date
- 07-05-2024
- Publisher
- Springer Berlin Heidelberg
- Published in
-
European Journal of Nuclear Medicine and Molecular Imaging
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089 - DOI
- https://doi.org/10.1007/s00259-024-06739-1